advanceCOR - GPVI-Inhibitory Antibodies
Our GPVI-inhibiting antibodies follow a completely new mode of action. They prevent activation of blood platelets and are thus supposed to protect against heart attacks and strokes. They have proven their high specificity and effectiveness in animal models without increased bleeding complications.
-
Most popular related searches
Product Details
In addition to Revacept, advanceCOR is developing another approach to inhibit the attachment of platelets to the wall of a blood vessel. While Revacept blocks the GPVI attachment site in the vessel wall and covers it like a patch, the second approach is to block the GPVI itself. To this end, advanceCOR has developed highly specific antibodies in a collaboration with Morphosys AG. Such antibodies can inhibit the function of GPVI.
Highly specific antibody fragments were obtained from the Ylanthia-Fab antibody library of Morphosys AG. These are so-called fully human antibodies. Such fully human antibodies contain only sequences from human antibodies and are therefore more tolerable than the previously widely used antibodies, which contain more or less large proportions of animal antibodies. advanceCOR has received an exclusive licence from Morphosys for these highly specific, modern antibodies and is now developing them further as novel drugs for the treatment of heart attack and stroke.
All pre-clinical trials with these antibodies have been very promising, both in terms of efficacy, safety and tolerability. Laboratory studies have effectively prevented the formation of blood clots in arteries. Similar to Revacept, these antibodies do not lead to a systemic influence on general haemostasis.
Further laboratory experiments with human tissue were carried out by the research group led by Prof. Dr. Wolfgang Siess at the University of Munich Hospital. The researchers allowed human blood to flow over damaged segments of blood vessels that had been surgically removed from patients during their treatment. It was shown that GPVI antibodies inhibit the attachment of platelets to the damaged vessel walls. These results were published in the renowned American Journal of the American College of Cardiology (http://www.sciencedirect.com/¬science/article/¬pii/S0735109715018471). A discussion of these exclusive new developments of advanceCOR can be found in an accompanying editorial by Neal S. Kleiman and Kumaran Kolandaivelu in the same journal (https://www.jacc.org/¬doi/pdf/10.1016/j.jacc.¬2015.03.576).
At advanceCOR we are currently establishing GMP-compliant production of the antibodies in precisely controlled cell lines. This will allow us to carry out the necessary safety and toxicity studies on these antibodies, which will then be used in clinical trials.
Customer reviews
No reviews were found for advanceCOR - GPVI-Inhibitory Antibodies. Be the first to review!